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Abstract
Background: Except during a 1-year period when BCG vaccine was not routinely administered, annual coverage of infants
with Bacillus Calmette-Gue ´rin (BCG) in Kazakhstan since 2002 has exceeded 95%. BCG preparations from different sources
(Japan, Serbia, and Russia) or none were used exclusively in comparable 7-month time-frames, September through March, in
4 successive years beginning in 2002. Our objective was to assess relative effectiveness of BCG immunization.
Methods/Findings: We compared outcomes of birth cohorts from the 4 time-frames retrospectively. Three cohorts received
vaccine from one of three manufacturers exclusively, and one cohort was not vaccinated. Cohorts were followed for 3 years
for notifications of clinical TB and of culture-confirmed TB, and for 21 months for TB meningitis notifications. Prevention
effectiveness based on relative risk of TB incidence was calculated for each vaccinated cohort compared to the non-
vaccinated cohort. Although there were differences in prevention effectiveness observed among the three BCG vaccines,
all were protective. The Japanese vaccine (currently used in Kazakhstan), the Serbian vaccine, and the Russian vaccine
respectively were 69%, 43%, and 22% effective with respect to clinical TB notifications, and 92%, 82%, and 51% effective
with respect to culture confirmed TB. All three vaccines were .70% effective with respect to TB meningitis.
Limitations: Potential limitations included considerations that 1) the methodology used was retrospective, 2) multiple risk
factors could have varied between cohorts and affected prevention effectiveness measures, 3) most cases were clinically
diagnosed, and TB culture-positive case numbers and TB meningitis case numbers were sparse, and 4) small variations in
reported population TB burden could have affected relative risk of exposure for cohorts.
Conclusions/Significance: All three BCG vaccines evaluated were protective against TB, and prevention effectiveness varied
by manufacturer. When setting national immunization policy, consideration should be given to prevention effectiveness of
BCG preparations.
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Introduction
Background
Since 1921, Bacillus Calmette-Gue ´rin (BCG) vaccine has been
given to infants to reduce the risk of tuberculosis (TB) disease, and
disseminated TB [1]. Generally, prospective randomized trials of
BCG have been used to evaluate efficacy of BCG, and
retrospective case-control studies of BCG have been used to
compare effectiveness of different BCG vaccine strains. Although
measures of BCG prevention effectiveness/efficacy have not been
consistent [2], when BCG immunization of newborns was
stopped in Sweden, a circumstance that provided a non-
vaccinated comparison group, a six-fold increase in TB
notifications was observed in infants [3]. In a prospective
randomized control trial in Britain in which over 50,000 older
children were allocated to no vaccination or one of two vaccine
groups, comparable prevention efficacy of 81% to 84% was
found among those vaccinated with BCG (Mycobacterium bovis)o r
with vole bacillus (Mycobacterium microti), respectively, when data
were compared over a 20-year period [4]. However, in another
randomized control trial in India in which over 100,000
uninfected subjects with a normal chest radiograph were
allocated to placebo or one of four vaccine groups, no difference
was observed in TB incidence among cohorts immunized with a
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dose or high-dose French BCG strain [5]. In an extensive review
in 1983 of eight prospective BCG trials (in the majority of which
positive prevention efficacy with BCG was found), the two trials
that rated highly in all examined aspects of methodological and
statistical quality reported prevention efficacy for TB of 76% or
more [6]. In a later meta-analysis of 14 prospective trials,
prevention efficacy for TB for BCG recipients was 51% (95%
confidence interval [CI], 30% to 66%) [1]. In the same meta-
analysis, seven trials reporting TB deaths showed prevention
efficacy of BCG vaccine of 71% (95% CI, 47% to 84%), and five
trials reporting on meningitis showed prevention efficacy of BCG
vaccine of 64% (95% CI, 30% to 82%) [1]. Differences in relative
prevention effectiveness between BCG preparations have been
described in two case-control studies with different vaccines, but
these studies have lacked non-vaccinated comparison groups for
estimating absolute effectiveness [7,8].
From the mid-1960s until 2003, BCG vaccine produced in
Russia was administered routinely at birth to all infants in
Kazakhstan. Since 2001, in years when there has been a BCG
immunization program in place for the full 12 months, reported
BCG coverage of infants in Kazakhstan has ranged from 95% in
2001, to 99% in 2002, 2003, 2006, and 2007 [9]; since 1997, the
published World Health Organization estimates of BCG
coverage have been consistent with the official reported BCG
coverage rates for Kazakhstan [9]. Although administration
mode data are not gathered routinely, the standard practice in
Kazakhstan is intradermal delivery of this vaccine. Beginning in
March 2003, the Government of Kazakhstan gradually changed
its BCG vaccine procurement source from its Russian source,–
Microgen, the Federal State Scientific-Industrial Company for
Immunobiological Medicines, an enterprise of the Ministry of
Health (MOH) of the Russian Federation, to a Serbian source,–
Torlak Institute of Immunology and Virology, a global producer
of vaccines and biopharmaceuticals in Belgrade. The change in
source was associated with 1,282 reports of adverse post-
vaccination events in newborns in 2003; of these, 1,260 (98%)
were reports of lymphadenitis. A subsequent investigation yielded
reported cases of lymphadenitis in 1.5% (26/1,747) of children
vaccinated with the Serbian BCG compared to 0.02% (1/4,217)
of children vaccinated with the Russian BCG (RR=62.6 (95%
CI: 8.5–462.1); p,0.001) (Kazakhstan MOH, unpublished data).
As a result, the Kazakhstan MOH issued a decree in February
2004 suspending use of the Serbian BCG vaccine. The Russian
BCG continued to be administered to fewer than 5% of
newborns, but after reports of adverse events in 54 children
given the Russian BCG between May and July 2004, the MOH
completely suspended the use of BCG vaccine on July 30, 2004.
From August 2004 to March 2005, the BCG vaccination
program in Kazakhstan was mostly disbanded (Figure 1). As a
consequence, the reported BCG coverage of infants in Kazakh-
stan decreased to 65% in 204 and 69% in 2005 [9]. However, in
mid-March 2005, infant vaccination with BCG resumed, with
vaccine produced by Japan BCG Laboratory (Tokyo), and use of
this vaccine has continued into 2011. For the cohort that was not
vaccinated with BCG in 2004–2005, there was no national
‘‘catch-up’’ vaccination campaign. Nevertheless, some oblasts
provided immunization for free for non-vaccinated children in
response to parental request; however, these measures were not
systematic.
Objective
Because assessing differences in relative effectiveness of
different BCG vaccines would be of value in allocating resources
in resource-constrained countries where TB is highly endemic,
the objective of this study was to assess whether there were
differences in the relative prevention effectiveness of BCG
vaccines produced by three different manufacturers and admin-
istered from 2002 through 2006 in the context an intradermal
BCG vaccination program in which there were no major
identifiable changes other than the addition or subtraction of
specific BCG vaccines.
Figure 1. Cohorts of vaccinated and non-vaccinated children in Kazakhstan, 2002–2006.
doi:10.1371/journal.pone.0032567.g001
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Overall
We used vaccination, TB notifications, and laboratory data for
four different cohorts of children. Three cohorts had received one
of the three BCG preparations intradermally, and one cohort had
received no BCG. Each cohort was followed over comparable
time-frames in successive years using three different TB reporting
models. The first model included clinically-defined, radiologically-
confirmed cases, the second was restricted to laboratory-confirmed
cases, and the third was restricted to reported cases of TB
meningitis. Because it was possible for a given case to be in more
than one model, there was overlap between the models.
Populations Studied and Ethics Approval
National TB data were obtained from aggregated surveillance
statistics published annually by the Kazakhstan National Tuber-
culosis Center [10], and as such, this activity was determined to be
program evaluation and not human subjects research. General
population estimates, and estimates of the number of children in
successive cohorts were obtained from publications of the
Republic of Kazakhstan National Statistics Agency [11]. All
personal information was removed from national TB surveillance
data before analysis. In addition, human subjects review and
ethical approval for these analyses were obtained from the U.S.
Centers for Disease Control and Prevention (CDC), which
determined that this project was program evaluation and not
human subjects research.
Data Sources and Overall TB Rates
The Kazakhstan MOH has included surveillance strengthening
as an important component of its directly observed therapy, short-
course (DOTS) program implementation. As a joint public health
program development effort, national case-based, disease-specific
electronic surveillance was first implemented in 1998 by the
MOH, with the support of CDC and the U.S. Agency for
International Development (USAID), to collect and analyze data
necessary to monitor and evaluate key TB program activities.
Development and adaption of Kazakhstan’s TB Electronic
Surveillance and Case Management (ESCM) system have
included development of electronic software in compliance with
WHO requirements for national case-based surveillance. The
ESCM system was evaluated jointly by the MOH and CDC in
2003 and 2006, and comparisons of completeness of reporting of
the electronic and paper-based surveillance systems favored the
electronic system, supporting discontinuation of traditional paper-
based surveillance and continuation of the ESCM.
In this study, published aggregated/unlinked data were used
from the ESCM system from 2002–2009, and included notifica-
tions of 300,098 TB cases. The following variables were used in
the analysis: date of birth, date of case notification, radiological
confirmed TB disease, TB meningitis, culture of sputum or gastric
aspirate, and laboratory confirmation of TB (culture positivity).
Data collection was performed by the Government of Kazakhstan.
CDC and the International Vaccine Institute participated
collaboratively with the Government of Kazakhstan in study
design, analysis, interpretation of data, and decision to submit the
work for publication.
Study Design
This study was a retrospective comparison of outcomes of four
different birth cohorts. For the period 2002–2006, outcomes of
three cohorts of BCG-vaccinated children (September 2002–
March 2003, September 2003–March 2004, September 2005–
March 2006) and one cohort of non-vaccinated children
(September 2004–March 2005) were analyzed. Births and
inclusion in each new cohort began on September 1 of a given
year and ended on March 31 of the subsequent year (Figure 1).
The cohorts and follow-up periods are described in Table 1. We
estimated the number of births for the 7-month cohorts as: [(the
number of live births in each year of the study412)64]+[(number
of live births in the following year412)63]; thus, a 4-month
estimate of the number of live births from September through
December in any given year was added to a 3-month estimate of
the number of live births from January through March in the
subsequent year. The 7-month inclusion period for each cohort
was succeeded immediately by a 29-month follow-up period
during which time the cohort was followed, yielding a total
potential cohort inclusion and follow-up time of 3 years. The
respective cohorts were followed for the full 3 years for TB
incidence, both for notification of clinical or culture-positive cases,
and for 21 months for notifications of TB meningitis. Hence, the
numbers of clinical cases and the numbers of culture-positive cases
for the different cohorts during the follow-up periods included all
cases diagnosed in a cohort between the first day of the cohort
inclusion period and a final day 3 years later, and for TB
meningitis, the cases diagnosed in a cohort between the first day of
the cohort inclusion period and a day 21 months later.
Laboratory-confirmed data were based on TB culture results
routinely reported to the ESCM system by TB hospital
laboratories. Because these were strictly surveillance data, no
attempt was made to standardize the reports among oblasts for
scientific analyses, for variation because of equipment limitation,
or for variations in training levels of laboratory personnel. Because
of diagnostic challenges and difficulties inherent in sputum
collection in the pediatric population, we also examined TB
notification data for older children and adults (persons aged 15–44
years and 45+) for the years 2002–2007 to determine if reported
incidence rates changed in this population, in the event that factors
other than changes in BCG vaccine type could account for any
changes in incidence observed in the four birth cohorts.
Because there was no national ‘‘catch-up’’ immunization
campaign for the non-vaccinated cohort, data regarding the
numbers of children in this cohort who were subsequently
vaccinated with BCG were not systematically gathered and were
not available for analysis.
Analysis
To assess BCG effectiveness for each vaccinated cohort, we
calculated relative risk (RR) for each of three models as the ratio of
p1 (the risk of having developed TB [a notification] or the risk of
having developed culture-confirmed TB or the risk of having
developed TB meningitis) to p2 (the risk observed in the non-
vaccinated cohort). The confidence interval (CI) for RR was
calculated taking the natural logarithm of the estimate of RR as
loge(RR)~loge(p1=p2)~loge(an2=cn1),
where ‘‘a’’ was the estimated number of TB cases in a given
vaccinated cohort, ‘‘n1’’ was the number of births in the
vaccinated cohort, ‘‘c’’ was the number of cases in the non-
vaccinated cohort, and ‘‘n2’’ was the number of births in the non-
vaccinated cohort. The standard error (SE) of the natural
logarithm of RR was estimated as
SE½loge(RR) ~ ﬃ p ½(b=an1)z(d=cn2) 
BCG Effectiveness in Children in Kazakhstan
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32567where ‘‘b’’ was the number of non-cases in the vaccinated cohort
and ‘‘d’’ was the number of non-cases in the non-vaccinated
cohort [12].
The 95% CI for loge (RR) was computed as loge
(RR)=61.96 SE, and the 95% CI for RR was obtained by
taking anti-logarithms. Finally, BCG prevention effectiveness
was calculated as (12RR)6100. Prevention effectiveness was
calculated for each of the three models: clinical TB, laboratory-
confirmed TB, and TB meningitis. The lower boundary for the
95% CI for prevention effectiveness was calculated as the upper
limit of the 95% CI of the RR, and the upper boundary for the
95% CI for prevention effectiveness was calculated as the lower
limit of the 95% CI of RR. All p-values were calculated as two-
tailed.
Kazakhstan has 16 administrative territories: two cities and 14
oblasts (provinces). To determine if there were regional variations
in prevention effectiveness, high TB prevalence oblasts ($4.02/
1,000; range: 4.03–4.34) were compared collectively with low TB
prevalence oblasts (#2.99/1,000; range: 1.69–2.95) with respect to
RR and prevention effectiveness of the three BCG vaccines for the
entire 3-year follow-up period in the four different cohorts. High
prevalence oblasts included Atyrauskaya, Kyzylordinskaya, Man-
gistauskaya, West Kazakhstan, and Zhambylskaya oblasts; low
prevalence oblasts included Almatinskaya, East Kazakhstan,
North Kazakhstan, and South Kazakhstan oblasts.
Because of concerns that variations in TB incidence observed
between the cohorts may reflect surveillance or TB incidence
phenomena across the general population, TB notification data for
older children and adults were examined for each of the years
2002–2007.
Results
The number of newborns in each cohort ranged from 138,059
to 168,664 in the four respective 7-month periods examined
(Table 1).
Cohort A (the non-vaccinated group) served as the comparison
group for cohorts B, C, and D (Russian, Serbian, and Japanese
vaccines, respectively). Prevention effectiveness based on clinical
TB case notifications was 69% for the Japanese BCG, 43% for
Serbian BCG, and 22% for Russian BCG (Table 2).
Of the 784 patients in the four cohorts who had specimens
cultured for TB, 20 (2.5%) had positive cultures (Table 3).
Estimates of prevention effectiveness levels based on laboratory-
confirmed TB cases were 92% for the Japanese BCG, 82% for
Serbian BCG, and 51% for Russian BCG.
BCG prevention effectiveness based on numbers of TB
meningitis case notifications for each vaccinated cohort ranged
from 71% to 89% (Table 4). Each vaccine had statistically
significant prevention effectiveness for TB meningitis when
compared with the outcomes of the non-vaccinated cohort.
The moving average (2-month) analysis of incidence rate based
on clinical case notifications in the cohorts demonstrated a rapid
increase in TB incidence during first year of life among non-
vaccinated children (Figure 2). The vaccinated cohorts had no
comparable increase. Relative to each vaccinated cohort, there
was an increased TB risk among the non-vaccinated cohort. The
three vaccines differed significantly in prevention effectiveness.
Survivor curve person-year (life table) analyses for TB
prevention among the BCG vaccinated and non-vaccinated
cohorts demonstrated significant prevention effectiveness for all
three vaccines with respect to developing disease resulting in TB
case notification (Figure 3). The cumulative percentage of cohort
members without TB during the first 1,000 days of follow-up
among non-vaccinated children was 0.9964%, but among the
cohort vaccinated with the Japanese vaccine, the percentage of
cohort members without TB during the first 1,000 days of the
follow-up period was 0.9996%, i.e., the vaccinated cohort had 32
more disease-free person-years per 10,000 person-years than the
non-vaccinated cohort had.
The prevention effectiveness hierarchy of manufacturers with
respect to clinical TB remained the same for the three vaccines
Table 1. Birth cohorts, BCG vaccine used, inclusive months of cohort entry, and length of follow-up, Kazakhstan, 2002–2008.
Cohort (vaccine used) and number of
newborns in cohort Inclusive months of cohort entry (births) Inclusive months of follow-up period
A (no BCG vaccine) n=160,970 Sep 2004–Mar 2005 Sep 2004–Aug 2007
B (‘‘Microgen’’, Russia) n=138,059 Sep 2002–Mar 2003 Sep 2002–Aug 2005
C (‘‘Torlak’’, Serbia) n=150,938 Sep 2003–Mar 2004 Sep 2003–Aug 2006
D (‘‘BCG laboratory’’, Japan) n=168,664 Sep 2005–Mar 2006 Sep 2005–Aug 2008
doi:10.1371/journal.pone.0032567.t001
Table 2. BCG vaccine prevention effectiveness for clinically defined, radiologically confirmed TB cases, Kazakhstan, 2002–2008.
Cohort (BCG
product) BCG Vaccinated Non-vaccinated (Cohort A) RR{ 95% CI{ for RR PE{ (%) p-value
# births
#
cases
Risk per
1000* # births
#
cases
Risk per
1000*
B Russian 138,059 207 1.50 160,970 310 1.93 0.78 0.65 0.93 22 0.005
C Serbian 150,938 165 1.09 160,970 310 1.93 0.57 0.47 0.69 43 ,0.001
D Japanese 168,664 102 0.60 160,970 310 1.93 0.31 0.25 0.39 69 ,0.001
*Risk calculated for the entire follow-up period (3 years).
{RR, relative risk; CI, confidence interval; PE, prevention effectiveness.
doi:10.1371/journal.pone.0032567.t002
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low TB prevalence oblasts (Table 5).
TB notification data for older children and adults showed little
variation across the years examined. For persons aged 15–44
years, the numbers of cases reported for the first time for the years
2002–2007 were respectively 27,054; 30,230; 30,003; 30,202;
28,452; and 27,024. For persons aged 45+ years, the numbers of
cases reported for the first time for the years 2002–2007 were
respectively 9,194; 10,646; 10,841; 11,451; 10,972; and 10,475.
Discussion
The study data demonstrate positive but differing prevention
effectiveness for clinical TB (22%, 43%, 69%) in Kazakhstan for
BCG vaccines from three producers, comparing outcomes of three
vaccinated cohorts of infants with those of a non-vaccinated
cohort; during the time-frames studied, modification of BCG
sources and a 7-month suspension of BCG administration were
the only externally imposed variations in an otherwise unmodified
national TB prevention program. The prevention effectiveness
hierarchy of manufacturers for clinical TB was the same whether
one were evaluating areas of high- or low-TB prevalence. All three
BCG vaccines were also protective but with differing effectiveness
observed for culture-confirmed TB and for TB meningitis.
Published case-control studies have yielded widely disparate
measures of protection from different BCG vaccines, ranging from
no reduction [13] to an 83% reduction [14] in TB incidence. In
1994, George Comstock proposed using a controlled methodology
to measure relative vaccine efficacy changes in geographic areas in
which the BCG vaccine had been recently changed [15], noting
that ‘‘…countries that have a need for vaccination and that
vaccinate at birth could be recruited to use their own vaccine in
even years and a different vaccine in odd years without making
any other changes in their vaccination programs. Merely
accumulating reported cases and deaths among persons born in
these even and odd years would reflect effects of the vaccines.’’
The use of three different BCG vaccines within a relatively short
period of time and the interruption of a BCG vaccination program
yielded non-vaccinated and vaccinated cohorts that provided a
unique opportunity to evaluate the effectiveness of BCG vaccines
in a model that resembled the one proposed by Comstock: the
experience of three different infant cohorts, each vaccinated with a
different BCG product, could be compared with that of a non-
vaccinated cohort; very large numbers included in each cohort
(range: 138,059–168,664) provided adequate sample sizes for
statistical analysis; the retrospective approach to identifying study
cohorts avoided the ethical quandary of using a vaccine strategy in
infants that did not include BCG; the vaccinated populations
studied were newborns and relatively mycobacteria-naı ¨ve, in
comparison to older children or adults who may have acquired
mycobacterial immunity and whose inclusion might have reduced
the observed BCG effectiveness [16]; and the control (non-
vaccinated) cohort was drawn from the same population from
which the comparison (vaccinated) cohorts came.
Potential limitations of this study need to be considered. First,
the methodology used was a retrospective cohort study, but the
best method for determining the protective effect of a vaccine
would be a prospective, randomized, double-blind, placebo-
controlled trial; such studies are rarely performed because of their
difficulty and expense, and the intent of this study was to make a
relatively inexpensive effort to analyze previously gathered data to
shed light on the prevention effectiveness of each vaccine
preparation. In addition, a prospective trial that employed a
vaccine strategy arm that did not include BCG could potentially
be considered unethical, because BCG confers protection against
meningeal and disseminated TB disease in childhood [1,17,18].
Second, to interpret the measured effectiveness of BCG vaccine in
a program as a reflection of vaccine efficacy, one would have to
Table 3. BCG vaccine prevention effectiveness for culture positive TB cases, Kazakhstan, 2002–2008.
Cohort (BCG
product) BCG Vaccinated Non-vaccinated (Cohort A) RR{ 95% CI{ for RR PE{ (%) p-value
# births # cases Risk per 1000* # births # cases Risk per 1000*
B Russian 138,059 5 0.04 160,970 12 0.07 0.49 0.17 1.38 51 0.166
C Serbian 150,938 2 0.01 160,970 12 0.07 0.18 0.04 0.79 82 0.011
D Japanese 168,664 1 0.01 160,970 12 0.07 0.08 0.01 0.61 92 0.002
*Risk calculated for the entire follow-up period (3 years).
{RR, relative risk; CI, confidence interval; PE, prevention effectiveness.
doi:10.1371/journal.pone.0032567.t003
Table 4. BCG vaccine prevention effectiveness for TB meningitis cases, Kazakhstan, 2002–2008.
Cohort (BCG
product) BCG Vaccinated Non-vaccinated (Cohort A) RR{ 95% CI{ for RR
PE{
(%) p-value
# births # cases Risk per 1000* # births # cases Risk per 1000*
B Russian 138,059 2 0.01 160,970 10 0.06 0.23 0.05 1.05 77 0.040
C Serbian 150,938 1 0.01 160,970 10 0.06 0.11 0.01 0.86 89 0.009
D Japanese 168,664 3 0.02 160,970 10 0.06 0.29 0.08 1.05 71 0.043
*Risk calculated for the follow-up period specifically used for meningitis cases (21 months).
{RR, relative risk; CI, confidence interval; PE, prevention effectiveness.
doi:10.1371/journal.pone.0032567.t004
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children was similar with respect to potential risk factors for TB
exposure and infection. Although our comparison cohorts were
consistent in time and place, risk factors that could have varied
and affected the measures of prevention effectiveness observed
between cohorts included accuracy of diagnosis, exposure to
environmental mycobacteria, vaccine virulence, and transmissi-
bility of locally endemic TB strains, household exposure risk, and
population genetics. Indeed, studies using the same BCG strain in
different countries have yielded varying levels of protection [19].
Although there was no reason to assume that exposure to
circulating non-tuberculosis mycobacterium strains, transmissibil-
ity of locally endemic TB strains, diagnostic methods, or
population genetics and immunity would have appreciably varied
between the cohorts chosen, there were small but progressive year-
to-year decreases in population burden of TB disease that could
Figure 2. Moving average (2-month) TB notification rate of different birth cohorts born in September–March, by type of BCG
administered, Kazakhstan, 2002–2008.
doi:10.1371/journal.pone.0032567.g002
Figure 3. Survivor curve person-year analyses for reported incidence of active TB among different BCG vaccinated and non-
vaccinated birth cohorts, Kazakhstan, 2002–2008.
doi:10.1371/journal.pone.0032567.g003
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household exposure (and hence risk of primary infection, as
opposed to reactivated disease) for those cohorts. Third, most
cases were clinically diagnosed; this is commonly the case in
children, but pediatric clinical diagnoses are more subjective and
subject to more variation. Data for culture positive cases were
analyzed separately, but the numbers of culture-positive cases
were sparse and the CIs for prevention effectiveness for culture-
positive disease were wide. Similarly, when data for TB
meningitis cases were analyzed, the numbers of TB meningitis
cases were also sparse and the CIs for prevention effectiveness for
TB meningitis were wide. Fourth, small variations were noted in
TB notification data that could have reflected differences in
relative risk of exposure of the cohorts. Fifth, in a differential
diagnosis in the absence of laboratory confirmation, clinicians
may be influenced away from a TB diagnosis because of their
expectations of BCG effectiveness and their knowledge of a
child’s vaccination status, which would contribute to overesti-
mates of prevention effectiveness. However, clinicians were
unlikely to know which BCG a child received; thus, expectations
of BCG effectiveness would not have had an effect on the
differences in prevention effectiveness observed between the
vaccines. Sixth, because the non-vaccinated cohort was the
comparison group for each of the vaccinated cohorts, lack of
availability of data regarding any catch-up vaccination that
occurred in the non-vaccinated cohort would systematically bias
the data that were used in this analysis toward minimizing the
true prevention effectiveness of each of the vaccines in equal
measure.
Historically, demand for BCG led the Institute Pasteur to
distribute the original strain to the world before protocol standards
for culture were established [20]. Reduced efficacy has subse-
quently been reported for strains that have had greater numbers of
serial passages, and genetic differences have been noted between
strains that may explain the differences in reported prevention
effectiveness [21,22]. Indeed, in a recent randomized trial of three
different commonly used BCG vaccine strains, significant
differences were noted in the immune responses (numbers of
mycobacterium-specific polyfunctional and cytotoxic T cells, and
concentrations of Th1 cytokines) induced by the different vaccine
strains in newborns [23]; this work provides a potential
immunologic basis for the differences in prevention effectiveness
of the BCG vaccines observed in our morbidity data.
Evaluation of the effectiveness of BCG programs is important,
especially in developing countries, and identification of strains that
offer superior protection would have worldwide applicability,
especially for developing and transitional economies. Other
approaches outlined for improving existing BCG vaccination
strategies include modifying strains to express Mycobacterium
tuberculosis antigens with greater immunogenicity, and using
prime-boost strategies (supplemental to BCG administration) with
supplemental inoculation with viral vectors encoding M. tuberculosis
antigens or protein subunits [24,25]. In countries in which TB
incidence is very high, small increments BCG prevention
effectiveness could potentially prevent large numbers of TB cases
and their attendant high death rate, especially in children.
Conclusions
Three different BCG vaccine preparations were evaluated using
data gathered retrospectively and were found to be effective in
preventing TB disease. TB prevention effectiveness of BCGs varies
by manufacturer. The prevention effectiveness hierarchy of
manufacturers for clinical TB was the same whether one were
evaluating areas of high- or low-TB prevalence. Ascertaining the
relative effectiveness/efficacy of BCG vaccines from different
producers may have implications when setting national and global
policy, as use of strains that offer superior protection may be more
cost-effective.
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Table 5. Relative risk and TB prevention effectiveness of BCG vaccines in different birth cohorts in areas of low (#2.99/1,000) and
high ($4.02/1,000) reported TB incidence, Kazakhstan, 2002–2008.
Reported TB
incidence
1
Cohort (BCG
product) BCG Vaccinated Non-vaccinated (Cohort A) RR{ 95% CI for RR{
PE{
(%)
# births # cases Risk per 1000* # births # cases Risk per 1000*
Low (#2.99/1000) B Russian 68,209 61 0.89 80,489 92 1.14 0.78 0.57 1.08 22
C Serbian 75,333 48 0.64 80,489 92 1.14 0.56 0.39 0.79 44
D Japanese 84,245 34 0.40 80,489 92 1.14 0.35 0.24 0.52 65
High ($4.02/1000) B Russian 26,670 74 2.77 31,711 112 3.53 0.79 0.59 1.05 21
C Serbian 29,472 65 2.21 31,711 112 3.53 0.62 0.46 0.85 38
D Japanese 33,397 35 1.05 31,711 112 3.53 0.30 0.20 0.43 70
*Risk calculated for the entire follow-up period (3 years).
{RR, relative risk; CI, confidence interval; PE, prevention effectiveness.
1High reported TB incidence - five oblasts: Atyrauskaya, Kyzylordinskaya, Mangistauskaya, West Kazakhstan, and Zhambylskaya. Low reported TB incidence - four
oblasts: Almatinskaya, East Kazakhstan, North Kazakhstan, and South Kazakhstan.
doi:10.1371/journal.pone.0032567.t005
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